Puma Biotechnology(NASDAQ) PBYI

Puma Biotechnology, Inc. creates medicines to fight cancer. Its main pill helps people with breast cancer. The company also tests new lung cancer drugs.

Medicines Fighting Cancer

• NERLYNX: Oral drug approved for specific types of breast cancer; sold primarily in the United States.
• Alisertib: Investigational medicine currently being tested for lung and breast cancer treatment.
• Licensing Agreements: Rights granted to international partners to distribute therapies in over 60 countries.

Broadening the Treatment Pipeline

• In-licensed alisertib from Takeda Pharmaceutical Company Limited in Sept. 2022 to expand the drug pipeline.
• Initiated the Phase II clinical trial of alisertib for extensive stage small cell lung cancer in Feb. 2024.
• Commenced a Phase II clinical trial of alisertib for hormone receptor-positive breast cancer in Nov. 2024.
• Amended the Los Angeles office lease and terminated a San Francisco lease by March 31, 2026.

Reaching Doctors and Patients

Puma Biotechnology uses its own sales team of 38 specialists to sell its lead drug in the United States. It also works with several international partners to provide cancer treatments to patients across more than 60 countries.

Recent Financial Performance

• Total revenue reached $56.5 million for the three months ended June 30, 2026, up from $52.4 million in 2025.
• Research and development expenses were $18.9 million in the quarter ended June 30, 2026, up 22.3% year over year.
• Net income was $4.4 million for the six-month period ended June 30, 2026.
• The company paid its debt with Athyrium in full as of June 30, 2026.
• Cash and cash equivalents totaled $36.5 million as of June 30, 2026.

The Evolution of Puma

Puma Biotechnology has transitioned from a development-stage firm to a commercial entity focused on specialized cancer therapies. Its focus on in-licensing new candidates while maximizing current drug sales defines its current strategy.